23:02 , Nov 17, 2016 |  BC Innovations  |  Product R&D

Hemorrhaging targets

An analysis of the almost 5,000 abstracts set to be presented at the 2016 American Society of Hematology (ASH) meeting next month indicates this year’s hot topics in preclinical research include a spattering of new...
07:00 , Oct 20, 2016 |  BC Innovations  |  Product R&D

Chaperoning the DJ

  In the latest example of post-dopamine thinking in Parkinson’s disease, Cantabio Pharmaceuticals Inc. has moved upstream of the neurotransmitter with a strategy to block the protein misfolding and oxidative damage that drive neurodegeneration in...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

PnuBioVax: Phase I data

ImmunoBiology reported data from the double-blind, U.K. Phase I SPV-001 trial in 36 healthy volunteers showing that 3 injections of 200 and 500 ug intramuscular PnuBioVax given 28 days apart significantly increased total antibody response...
08:00 , Nov 12, 2015 |  BC Innovations  |  Product R&D

Crystallin-clear ViewPoint

By exploring the biophysics of proteins with disease-associated mutations, a UCSF group has developed a way to screen for drugs that rescue the activity of non-enzymatic targets, and proved its value with molecular chaperones. After...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

UbiVac, J&J deal

Johnson & Johnson’s Janssen Biotech Inc. unit partnered with UbiVac to develop preclinical and clinical versions of UbiVac’s DRibble immunotherapy technology to treat oral cancer. UbiVac will receive an upfront payment and is eligible for...
07:00 , Oct 3, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Heat shock protein 90 (Hsp90); heat shock 90 kDa protein b1 (Hsp90B1; GP96; GRP94) In vitro studies identified a purine-based specific inhibitor of the...
08:00 , Feb 20, 2012 |  BioCentury  |  Product Development

Turning up the heat(shock)

The majority of cancer therapeutics directed against heat shock proteins are focused on Hsp90 . OncoGenex Pharmaceuticals Inc. expects its OGX-427 , a first-in-class Hsp27 inhibitor, will elicit fewer side effects and will help prevent...
08:00 , Nov 14, 2011 |  BC Week In Review  |  Company News

ImmunoBiology, China National Pharmaceutical Group deal

ImmunoBiology partnered with Lanzhou Institute of Biological Product (LIBP) to co-develop ImmunoBiology's T-BioVax vaccine to treat tuberculosis (TB) in China. The vaccine is based on ImmunoBiology's ImmBioVax technology, which uses pathogen-derived heat shock proteins in...
08:00 , Nov 7, 2011 |  BioCentury  |  Emerging Company Profile

Orphazyme: One for all

Drug development for lysosomal storage disorders has largely centered on enzyme replacement therapies, which yield one drug per disease. Orphazyme ApS believes its recombinant heat shock protein 70 (Hsp70) and small molecules that induce heat...
07:00 , May 23, 2011 |  BC Week In Review  |  Company News

CytRx, Orphazyme deal

Orphazyme said the technology complements its development of heat shock protein-based therapies for lysosomal storage diseases, including lead compound Orph-001 , a recombinant version of the molecular chaperone heat shock protein 70 (Hsp70) in preclinical...